For Biosimilars, Profit's All In A Name

Law360, New York (June 5, 2012, 8:39 PM EDT) -- Would a drug by any other name sell as sweet? That's the big question as the U.S. Food and Drug Administration considers whether to make biosimilars take names different from their brand-name counterparts, and experts say the decision will have a big impact on the bottom lines of generics makers, brand-name drug companies and insurers. 

The success of biosimilars — and the cost savings insurers and other payors are hoping will follow — depends on how often they can be substituted for brand-name biologics. Most biosimilars...
To view the full article, register now.